Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/08/26	$1.380	+10.40%	52,243
14/08/26	$1.250	-4.58%	21,936
13/08/26	$1.310	+0.77%	54,292
12/08/26	$1.300	-7.14%	17,647
11/08/26	$1.400	+2.19%	37,226

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq 00:00:00 18/08/2026 +04			5-day change	1st Jan Change
1.380 ^USD	+10.40%		+0.73%	-74.54%

08-14	Exicure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-30	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026	CI

Market Cap	8.8M 7.59M 7.12M 6.49M 12.2M 841M 12.37M 83.51M 32.73M 421M 33.02M 32.31M 1.4B	P/E 2024	-2.88x	P/E 2025	-6.9x
Enterprise Value	5.23M 4.51M 4.23M 3.86M 7.25M 500M 7.35M 49.62M 19.44M 250M 19.62M 19.2M 833M	EV / Sales 2024	70.2x	EV / Sales 2025	-
Free-Float	55.9%	Yield 2024 *	-	Yield 2025	-

08-14	Exicure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-30	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026	CI
05-29	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Exicure announces co-development agreement with Adbiotech for burixafor (GPC-100)	RE
04-23	Exicure, Inc. And Adbiotech Co., Ltd. Enter Co-Development Agreement For Burixafor (GPC-100)	CI
04-11	Exicure, Inc. Announces Management Changes	CI
03-28	Exicure, Inc. Announces Resignation of Director Sangjin Yeo from Board and Audit Committee, Effective March 27, 2026	CI
03-26	Exicure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-25	Exicure, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-18	Exicure appoints Jung Soo Kim as CEO and president	RE
02-18	Exicure, Inc. Announces Executive Appointments, Effective February 11, 2026	CI
02-18	Exicure, Inc. Appoints Gyuyeob Lee as Interim Chief Financial Officer, Effective February 11, 2026	CI
02-18	Exicure, Inc. Appoints Jung Soo Kim as Chief Executive Officer, Effective February 11, 2026	CI

16/08/22	Chardan Adjusts Exicure's Price Target to $2 on 1-for-30 Reverse Stock Split, Maintains Neutral Rating	MT
29/03/22	Chardan Adjusts Exicure's Price Target to $0.25 From $0.40 'on Increased Dilution;' Neutral Rating Kept	MT
13/12/21	Chardan Downgrades Exicure to Neutral From Buy After Probe Shows Clinical Data Misrepresentation, Lowers PT to $0.40 From $2.25	MT
23/11/21	Chardan Adjusts Price Target on Exicure to $2.25 From $7 'on Uncertain Delays for Clinical Programs,' Keeps Buy Rating	MT
17/05/21	Exicure : HC Wainwright Adjusts Price Target on Exicure to $6 From $8, Maintains Buy Rating	MT

Exicure, Inc. Stock

Stocks

XCUR

US30205M3097

Biotechnology & Medical Research

Valuation: Exicure, Inc.

Chart: Exicure, Inc.

Latest news : Exicure, Inc.

Analysts' recommendations: Exicure, Inc.

Press Releases: Exicure, Inc.

News in other languages: Exicure, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Exicure, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

08-03	Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance	AQ
06-30	Exicure Announces Board and Committee Changes	AQ
06-11	Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement	AQ
06-02	Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q	AQ
04-23	Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)	AQ

02/08/21	Les valeurs à suivre aujourd'hui à Paris Lundi 2 août 2021
02/08/21	Ipsen : signe un partenariat avec Exicure dans les acides nucléiques sphériques
02/08/21	EN DIRECT DES MARCHES : Axa, Bolloré, Neoen, Ipsen, HSBC, Heineken, Square, Moderna...
02/08/21	Ipsen : accord de collaboration avec Exicure
02/08/21	Dernière ligne droite avant la coupure aoûtienne

1 day	+10.40%
1 week	+0.73%
Current month	-13.75%
1 month	-17.86%
3 months	-51.41%
6 months	-64.48%
Current year	-74.54%

1 week	1.18	1.42
1 month	1.18	2.02
Current year	1.18	6.64
1 year	1.18	9.48
3 years	1.18	36
5 years	1.18	217.5
10 years	1.18	975

Manager	Title	Age	Since
Jungsoo Kim CEO	Chief Executive Officer	-	11/02/2026
Gyuyeob Lee DFI	Director of Finance/CFO	40	11/02/2026
Josephine Cardarelli PSD	President	-	06/10/2025

Director	Title	Age	Since
Dong-Ho Lee BRD	Director/Board Member	64	21/08/2023
Gyeung Seog Cheon BRD	Director/Board Member	-	09/02/2026
Jungsoo Kim BRD	Director/Board Member	-	11/02/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
08/07/26	EXICURE HITRON, INC.	Others	Company	117,441	1.8589%
16/02/26	Josh Miller	Tax	Chief Accounting Officer	8	0.0001%
21/01/26	EXICURE HITRON, INC.	Sell	Company	258,367	4.0895%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXICURE, INC.	+10.40%	+0.73%	-79.25%	-66.35%	8.8M
WUXI APPTEC CO., LTD.	+4.80%	+3.44%	+70.64%	+109.32%	73.25B
ARGENX SE	-0.77%	+13.32%	+48.03%	+89.17%	61.95B
INSMED INCORPORATED	+3.70%	-4.77%	+0.41%	+484.07%	28.02B
WUXI BIOLOGICS (CAYMAN) INC.	+5.24%	+5.65%	+56.71%	+21.30%	24.15B
BIONTECH SE	-1.60%	-1.29%	-19.31%	-19.10%	23.01B
PHARMAESSENTIA CORPORATION	-6.00%	+6.02%	+244.39%	+430.80%	18.35B
GENMAB A/S	+0.88%	+6.62%	+40.96%	-13.44%	19.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.83%	+2.65%	+21.42%	+557.58%	15.92B
EXELIXIS, INC.	+2.11%	-1.21%	+36.57%	+149.14%	12.96B
Average	+2.26%	+1.03%	+42.06%	+174.25%	27.71B
Weighted average by Cap.	+1.78%	+3.14%	+54.79%	+164.65%

	2024	2025
Net sales	500K 432K 405K 369K 694K 47.81M 703K 4.75M 1.86M 23.95M 1.88M 1.84M 79.67M	-
Net income	-9.7M -8.37M -7.86M -7.16M -13.46M -928M -13.64M -92.1M -36.09M -465M -36.42M -35.63M -1.55B	-4.95M -4.27M -4.01M -3.65M -6.86M -473M -6.96M -46.96M -18.4M -237M -18.57M -18.17M -788M
Net Debt	-6.46M -5.58M -5.24M -4.77M -8.97M -618M -9.09M -61.37M -24.05M -310M -24.27M -23.74M -1.03B	-3.57M -3.08M -2.89M -2.63M -4.95M -341M -5.02M -33.89M -13.28M -171M -13.4M -13.11M -569M